 |
 | Sol J. Barer, Ph.D.
Executive Chairman
Dr. Barer is the Executive Chairman of Celgene. He was Chief Executive Officer from May 1, 2006 until June 16, 2010 when he transitioned to his current position. Previously he was appointed President in 1993, and Chief Operating Officer and Director in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr Barer joined the Celanese Research Company in 1974 and formed the Biotechnology group that was subsequently spun out to form Celgene.
Dr. Barer also serves on the Board of Directors of Amicus Therapeutics, the Board of Trustees of BioNJ, the Board of the Brooklyn College Foundation, the Board of Trustees of Rutgers - The State University of New Jersey and the Board of the Tourette Syndrome Association. He has previously served as a Commissioner of the NJ Commission on Science and Technology.
Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University and B.S. from Brooklyn College.
| |  | Robert J. Hugin
President and Chief Executive Officer
Robert J. Hugin has been our President and Chief Executive Officer since June 16, 2010. He was previously President and Chief Operating Officer between May 1, 2006 and June 16, 2010, and was elected by the Board of Directors to serve as a Director in December 2001. Mr. Hugin served as Senior Vice President and Chief Financial Officer from June 1999 to May 1, 2006. Previously, Mr. Hugin had been a Managing Director at J.P. Morgan & Co. Inc., which he joined in 1985. He received an A.B. degree from Princeton University in 1976 and an M.B.A. from the University of Virginia in 1985 having served as a United States Marine Corps infantry officer during the intervening period. Mr. Hugin also serves on the Board of Directors of PhRMA, The Medicines Company, Atlantic Health System Inc. and Family Promise, a national non-profit network assisting homeless families, and is past chairman of the HealthCare Institute of New Jersey. | |  | Michael D. Casey
Former President and Chief Executive Officer of Matrix Pharmaceutical, Inc.
Michael D. Casey has served as one of our Directors since August 2002 and is a member of the Nominating and Governance Committee, Executive Committee and Compensation Committee. From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a Director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the Retail and Specialty Products Division of Schein. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a Director of Allos Therapeutics, Inc., Cholestech Corporation, OrthoLogic Corp. and Durect Corp. | |  | Rodman L. Drake
Managing Director CIP Management
Rodman L. Drake was named to the Celgene Board of Directors in April 2006, and serves as a member of the Nominating and Compensation Committees. Mr. Drake has been Managing Director of Baringo Capital LLC, a private equity firm since 1997. Prior to that, he was Co-Chairman for the KMR Power Company and Chief Executive Officer and Managing Director of Cresap McCormick and Paget. In addition, Mr. Drake is a Director of Jackson Hewitt, Student Loan Corporation, The Hyperion Brookfield Funds, The Columbia Atlantic Funds, and Animal Medical Center in New York. | |  | Gilla Kaplan, Ph.D.
Professor and Full Member In the Laboratory of Mycobacterial Immunity and Pathogenesis at the Public Health Research Institute Center at UMDNJ
Gilla Kaplan Ph.D. has been one of our Directors since April 1998 and is a member of the Audit Committee of our Board of Directors. She is head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark, New Jersey, where she was appointed full member in 2002. Dr. Kaplan is also Professor of Medicine at UMDNJ. Previously, Dr. Kaplan was an Immunologist in the Laboratory of Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor. | |  | Walter L. Robb, Ph.D.
President of Vantage Management Inc., Previously Senior Vice President for Corporate Research and Development of General Electric Company
Walter L. Robb, Ph.D., one of our Directors since 1992 and a member of the Audit Committee of our Board of Directors, has been a private consultant and President of Vantage Management Inc., a consulting and investor services company, since January 1993. Dr. Robb was Senior Vice President for Corporate Research and Development of General Electric Company, and a member of its Corporate Executive Council from 1986 to December 1992. Dr. Robb is Chairman of the Board of Directors of Capital District Sports. He is also a Director of Mechanical Technology, Inc. and several private companies. | |  | James Loughlin
Former Chairman, Pension and Investment Committee of the KPMG Board
Jim Loughlin was named to the Celgene Board of Directors in January 2007, and serves as a member of the Audit Committee. Mr. Loughlin, an experienced corporate director served as the National Director of the Pharmaceuticals Practice at KPMG, including a five-year term as member of the Board of Directors of KPMG LLP. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. | |  | Ernest Mario, Ph.D.
Former Deputy Chairman and Chief Executive of Glaxo Holdings plc.
Ernest Mario, Ph.D., joined the Board of Directors in August 2007 and serves on the Nominating and Governance and Executive Committees. Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc.and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario has been a Director of Boston Scientific since October 2001 and is currently Chairman of Pharmaceutical Product Development. From 2003 to 2007, he was Chairman and Chief Executive of Reliant Pharmaceuticals. Dr. Mario was recently appointed the Chief Executive Officer of Capnia, Inc. A former Trustee of Duke University, he serves on the Board of the Duke University Health System. He is a past Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to the pharmacy schools at the University of Maryland, the University of Rhode Island and The Ernest Mario School of Pharmacy at Rutgers University. Dr. Mario is the recipient of the 2007 Remington Medal. | |  | Carrie S. Cox
Former Executive Vice President and President of Schering-Plough’s Global Pharmaceutical Business
In her nearly 30-year career in the pharmaceutical industry, Cox has led numerous businesses, with a track record of building high-performance teams that drive growth and global success. In her most recent role as executive vice president and president of Schering-Plough’s Global Pharmaceutical Business (2003 - 2009), Cox led the transformation of that business, more than doubling its annual sales to $16 billion in annual revenue. Her team delivered a 22% CAGR over a five-year period, and drove the company’s 13 consecutive quarters of double-digit eps growth. Prior to joining Schering-Plough, Cox served as president of Pharmacia Corporation’s $12 billion global pharmaceutical business until its merger with Pfizer in 2003. Carrie joined U.K.-based Pharmacia and Upjohn (Pharmacia’s predecessor company) in 1997 as a senior vice president, and was a principal driver of that company’s dramatic turnaround, and later merger, with Monsanto Corporation and its Searle pharmaceuticals division.
She has received numerous industry awards, and FORTUNE magazine named Carrie to its List of the “50 Most Powerful Women in Business” on six separate occasions, including five consecutive years since 2005. Carrie is a member of the Board of Directors of Texas Instruments and has served on their audit and compensation committees as well as being named to the Board of Directors of Cardinal Health. She is a member of the Harvard School of Public Health’s Health Policy and Management Executive Council and is a member of the Board of Overseers of the University of Pennsylvania Museum of Archaeology and Anthropology. Cox is a pharmacist, with a pharmacy degree from Massachusetts College of Pharmacy in 1981.
| |
|
